Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 155.17 USD -0.21% Market Closed
Market Cap: 373.6B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Johnson & Johnson
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Gross Profit
$60.7B
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Gross Profit
$36B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Gross Profit
$42.6B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Gross Profit
$48.4B
CAGR 3-Years
15%
CAGR 5-Years
8%
CAGR 10-Years
6%
Zoetis Inc
NYSE:ZTS
Gross Profit
$6.4B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Gross Profit
$33.1B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
8%
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
373.5B USD
Industry
Pharmaceuticals

Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a competitive landscape, ensuring sustained revenue growth and profitability. For investors, Johnson & Johnson represents a compelling opportunity not only due to its diversified business model but also its robust financial health. The company boasts a history of steady revenue growth, strong cash flow generation, and a reliable dividend, making it a perennial favorite for income-focused investors. While it has faced some legal challenges and market pressures, J&J’s ability to adapt and respond to these issues has underscored its resilience. With a strong balance sheet and a global footprint in the ever-growing healthcare sector, Johnson & Johnson continues to demonstrate why it is often regarded as a cornerstone investment in a well-rounded portfolio.

JNJ Intrinsic Value
159.74 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Gross Profit?
Gross Profit
60.7B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Gross Profit amounts to 60.7B USD.

What is Johnson & Johnson's Gross Profit growth rate?
Gross Profit CAGR 10Y
2%

Over the last year, the Gross Profit growth was 4%. The average annual Gross Profit growth rates for Johnson & Johnson have been -1% over the past three years , 2% over the past five years , and 2% over the past ten years .

Back to Top